Business
HDFC Securities recommends ten stocks for Samvat 2083 Muhurat trading session
Reported by Ananya Das (Senior Writer) · Livemint - Markets ·
HDFC Securities has released a list of ten stocks recommended for purchase during the special Samvat 2083 Muhurat trading session on Sunday, 8 November, with the National Stock Exchange and Bombay Stock Exchange opening at 2:20 PM IST. The brokerage selected these companies across sectors including cement, power, energy, defence, automobiles, housing finance, textiles, metals, pharmaceuticals and infrastructure, citing growth prospects, improving operational efficiencies, healthy order books and favourable industry trends.
Stock Picks And Targets
For Ambuja Cement, the broker suggests a buy range of ₹347 to ₹362, an add-on dips price of ₹325, and a target price of ₹481, driven by higher green-power usage and logistics efficiencies. Adani Power carries a buy range of ₹185 to ₹195, a dip price of ₹170, and a target of ₹234, supported by long-term power purchase agreements and disciplined leverage. Coal India has a buy range of ₹389 to ₹405, a dip price of ₹355, and a target price of ₹490, backed by robust volume outlook and e-auction premiums. Bharat Electronics is recommended at a buy range of ₹368 to ₹378 with a target of ₹475, aided by a debt-free balance sheet and strong order book. Maruti Suzuki India has a buy range of ₹11,200 to ₹11,600, a dip price of ₹10,400, and a target price of ₹13,904, supported by export growth and capacity additions. Can Fin Homes is pegged with a buy range of ₹720 to ₹740, a dip price of ₹655, and a target of ₹845, backed by planned branch additions and direct sourcing.
Context
Muhurat trading is a traditional symbolic stock market session held in India during Diwali to welcome prosperity and mark the beginning of the Hindu calendar year Samvat. Brokerages routinely issue curated stock recommendations ahead of this session for investors looking to hold equities across the festival year.
More in Business
BusinessSource: Business StandardImportant
Zydus Lifesciences reports lower net profit in second quarter despite higher revenue.
Reported by Kavya Rao (Senior Writer) · Business Standard - Top Stories ·

